Evidence map›Paper›PMID 42774366›Full record

ArticleFrontiers in immunology2026

H3K18la facilitates nasopharyngeal carcinoma progression through the activation of the IGF2BP1-COX2 signaling pathway.

Zhaomeng Guo, Dunhui Yang, Ruyu Niu, Lisi Su, Zhen Wang, Fang Ma, Peng Zhang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhaomeng Guo *Department of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Dunhui Yang *Department of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Ruyu NiuDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Lisi SuDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Zhen WangDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Fang MaDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.
Peng ZhangDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital & Shenzhen Otolaryngology Research Institute, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from the nasopharyngeal epithelial mucosa, with its development closely associated with metabolic reprogramming. Lactylation, an epigenetic modification induced by lactate, plays a regulatory role in gene transcription.The precise function and mechanisms of H3K18la in NPC malignancy progression are yet to be clarified.This study demonstrates that the glycolytic pathway is markedly activated in NPC tissues, accompanied by elevated expression of H3K18la, which positively correlates with tumour stage. Subsequent studies showed that lactic acid production, mediated by lactate dehydrogenase A (LDHA), facilitates H3K18la modification. Inhibiting LDHA specifically leads to reduced H3K18la levels, suppressed proliferation of NPC cells, and increased apoptosis.H3K18la upregulates the RNA-binding protein IGF2BP1, while inhibiting LDHA or IGF2BP1 reduces COX2 mRNA stability and expression, influencing NPC cell proliferation and apoptosis resistance. In summary, this study indicates that H3K18la modification is crucial for NPC malignancy through the activation of the IGF2BP1-COX2 signaling pathway. This research elucidates lactylation modification mechanisms in NPC, presenting novel targets for its treatment.

Indexed as

Cyclooxygenase 2HistonesNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRNA-Binding ProteinsSignal TransductionApoptosisCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansLactate Dehydrogenase 5L-Lactate DehydrogenaseCyclooxygenase 2HistonesIGF2BP1 protein, humanLactate Dehydrogenase 5LDHA protein, humanL-Lactate DehydrogenasePTGS2 protein, humanRNA-Binding ProteinsCOX2H3K18laIGF2BP1lactatenasopharyngeal carcinoma

Identifiers

PMID42774366
PMCPMC13593861

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.